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COMMENTARY: PROFESSIONAL PEER
REVIEW AND THE ANTITRUST LAWS
William G. Kopit*
PROFFESSOR Havighurst's fundamental premise-that peer-review activities must be judged by their competitive effect-is a
critical point which is often overlooked by health care practitioners
and health care attorneys alike. There can no longer be any question that courts will evaluate peer review not by the worthiness of
the participant's goals or the public purpose which the goals embody, but on the impact of those activities in the marketplace. To
the extent that the impact is deemed pro-competitive, peer review
will withstand antitrust scrutiny. However, to the extent that the
impact is determined to be anti-competitive, peer review will be
judged violative of the antitrust laws. Professor Havighurst also
emphasizes that in making this fundamental determination courts
will primarily look at the consumer's interest rather than that of the
competitor. 1
Before entering into a discussion of the antitrust principles
themselves, it is perhaps useful to discuss two exemptions which
may apply to peer review activity: the business of insurance exemption and the implied repeal exemption.
Little time need be devoted to discussion of the business of insurance exemption, as the Supreme Court has clearly held that the
exemption does not apply.2 Union Labor Life Ins. Co. v. Pireno3
involved an antitrust challenge by a chiropractor to the chiropractic
association's determination that the plaintiff was involved in inappropriate utilization of chiropractic services. As those determina* Partner, Epstein Becker Borsody & Green, P.C., Washington, D.C. A.B., Bucknell
University (1961); J.D., Columbia University (1964).
1. While it has been virtually an antitrust cliche that the antitrust laws protect competition and not competitors, the case law often obscures or disregards this significant distinction. However, it is encouraging to note that the courts have given increased emphasis to this
principle. See, e.g., Matsuschita Elec. Indus. Co. v. Zenith Radio Corp., 106 S. Ct. 1348
(1986); Continental T.V., Inc. v. GTE Sylvania Inc., 433 U.S. 36 (1977).
2. Because much peer-review activity is undertaken pursuant to contract with one or
more insurance companies, it was at least arguable that contracts and activities undertaken in
accordance with those insurance contracts were exempt under the business of insurance provisions of the McCarran-Ferguson Act, 15 U.S.C. §§ 1011-1015.
3. 458 U.S. 119 (1982).
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tions were made under contract with the insurance company
providing for utilization review services, the insurance company
and the chiropractic association argued that they were exempt from
the antitrust laws under the business of insurance exemption.' The
Supreme Court, relying on Group Life & Health Insurance Co. v.
Royal Drug Co., determined that the contract for utilization review
was not part of the business of insurance.6
The implied repeal doctrine7 is the other possible exemption.
Professor Havighurst correctly recognizes that federally financed
and regulated peer review organizations (PROs) are protected with
regard to their performance of review over public programs. 8 However, Professor Havighurst states that immunity does not extend to
private review performed by PROs. In fact, the legislative history is
somewhat ambiguous. Specifically, it states:
The amendment facilitates the performance of private review by
requiring a peer review organization to make available its facilities and resources to private
payors paying for health care in its
9
area on a contract basis.
While this language can be read as merely permitting the use of
the facilities of the PRO rather than involving its standard setting
and review functions, it is at least possible that the language should
be interpreted to mean that PROs will perform private review upon
request. The latter interpretation perhaps will carry with it the implied repeal authority which extends to federal review.' 0 In any
event, even assuming there is immunity for PROs, such immunity
would not extend to other kinds of review organizations. 1
Thus, it is necessary to discuss the applicability of antitrust prin-

ciples to such PROs. In undertaking that analysis, it is important
4. Id. at 126.
5. 440 U.S. 205 (1979).
6. Pireno, 458 U.S. at 126, 134. The Court affirmed the Second Circuit's determination
on this point, and affirmed a remand to the district court for trial on the merits. Id. at 125,

134. However, the plaintiff was elected president of the chiropractic association and the case
was settled without ever coming to trial.
7. For an analysis of this doctrine in the context of the federal health planning laws, see
National Gerimedical Hosp. and Gerontology Center v. Blue Cross, 452 U.S. 378 (1981).
8. Professor Havighurst draws no distinction between Medicare and Medicaid. Yet,
PROs perform Medicaid review only at the election of the state.
9. S. REP. No. 494,97th Cong., 2d Sess. 42, reprintedin 1982 U.S. CODE CONG. & AD.

NEws 781, 818.
10. Congressman Wyden proposed a bill called the Health Care Quality Improvement
Act of 1986 that would extend peer review protection against the antitrust laws to a variety of
peer review organizations, rather than merely PROs. H.R. 5540, 99th Cong., 2d Sess., 132
CONG. REc. H7068 (Sept. 17, 1986). This bill may be reintroduced at the next session.
11. But see supra note 10.
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to distinguish peer review from fee review. Peer review is the process whereby standards for medical practice relating to appropriate
utilization and quality of care are established and individual practitioners are judged for compliance with those standards. In contrast, fee review is the process whereby fees for particular services
are retrospectively reviewed for their reasonableness. Professor
Havighurst indicates that fee review should be unobjectionable so
long as it continues to be retrospective in its application."2 However, the distinction between the two situations here is somewhat
semantic. Plainly, the first time the organization determines that a
fee is unreasonably high that determination is retrospective. To the
extent that determination is made publicly available, establishment
of the maximum would appear to be prospective with regard to subsequent fees for the same type of service.
In contrast, the establishment of standards regarding appropriate utilization or quality of care appears to be less subject to antitrust risks. Admittedly, the establishment of such standards, by
definition, "standardize" the product, but such standardization is
necessary to permit meaningful price comparisons. One procedure
may be half as expensive as another, but it cannot be viewed as a
meaningful substitute to the extent that it is inefficacious or
dangerous.
To be sure, it is not really necessary for professionals to dominate the decisionmaking process relating to the safety or efficacy of
a particular procedure or mode of treatment. However, it seems
reasonable that professionals are the best qualified to make such determinations in the final analysis.13
Whether the organization is involved in utilization review, quality review, or fee review, it appears to be relatively clear that antitrust liability should not attach so long as the organization is merely
recommending rather than undertaking any final determination. As
Professor Havighurst correctly perceives, the distinction is between
attempting to persuade the purchaser, which is clearly permissible
under the antitrust laws, and foreclosing competition by determin14
ing that a competitor has acted inappropriately.
12. Of course, Professor Havighurst would agree that to the extent the organization
prospectively established maximum fees, such activity could be viewed as price fixing, a per se
violation of § 1 of the Sherman Act. See Arizona v. Maricopa County Med. Found., 457 U.S.
332 (1982).
13. See Boyle, Regional Variationsin the Use of MedicalServices andAccountability of
the Profession, 254 J. A.M.A. 407 (1985).
14. In this case the purchaser is not the individual patient but the insurance company or
self-insured employer that has contracted with the PRO. There can be little question that
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The federal antitrust enforcement agencies have recognized the
legitimacy of this analysis in advisory opinions written to PROs.
For example, in a letter to the Rhode Island Professional Standards
Review Organization, Inc. (RIPSRO), the FTC advised the corporation that a peer-review program conducted by physicians to provide non-binding advice to insurers and other third-party payors of
health care claims would not violate the antitrust laws. 5 Focusing
on potential benefits to consumers, the FTC considered the RIPSRO peer-review program pro-competitive insofar as it provides incentives to third-party payors to implement cost-containment
16
programs and to providers to practice in a cost-conscious manner.
One of the benefits in limiting a PRO to making recommendations is that it may facilitate a reviewing court's ability to determine
that an antitrust action can be dismissed on a summary judgment
motion. Antitrust litigation is time-consuming and expensive, and,
in that sense, even a prevailing defendant can be a loser in practical
terms. Thus, the ability to obtain summary judgment is a significant benefit to a defendant, and PROs' limitation to recommendations rather than final decisions may permit the courts to more
easily grant such motions. Absent some form of coercion or established pattern of passive acceptance of all recommendations, the organization would simply claim that there were no facts under which
a violation could be established.
Assuming that the PRO has authority to make final decisions, it
does not follow that such determinations will necessarily be anticompetitive. The most difficult case relates to fee review because
such review carries with it many of the elements of price fixing. To
the extent a court determines that a distinction between such activities and the Maricopa'7 case are insignificant, then plainly the organization would be judged to violate the antitrust laws.
third parties do indeed meet the test for purchasers under the antitrust laws. See Kartell v.
Blue Shield, 749 F.2d 922, 925 (Ist Cir. 1984).
15. Letter from Emily H. Rock, Secretary, FTC to Edward J. Lynch (May 9, 1983),
reprintedin 101 F.T.C. 1010 (1983). The FTC's opinion is limited to § 5 of the FTC Act, 15
U.S.C. § 45(b), which prohibits unfair competition. The FTC Act is broader than the Sherman Act; thus, acts permissible under the FTC Act would be permissible under the Sherman
Act. See FTC v. Brown Shoe Co., 384 U.S. 316, 321-22 (1968).
16. See also Letter from Timothy Mudis, Director, Bureau of Competition, FTC to Norman Klombers (Aug. 18, 1983) (FTC approves peer-review program proposed by the American Podiatry Association to provide advisory opinions regarding necessity of medical services
and fees).
17. Arizona v. Maricopa County Med. Found., 457 U.S. 332 (1982) (holding that "maximum-fee agreements, as price-fixing agreements, are per se unlawful under § I of the Sherman Act").
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Peer-review activities relating to either quality or utilization
would not appear to be subject to the same risks. Admittedly, there
would be some anti-competitive effect because the provider's action
would be precluded. 8 Nevertheless, any anti-competitive effect
would appear to be more than offset by the pro-competitive purpose
of providing the consumer with a safe and efficacious product.
Thus, unless the plaintiff can establish particular evidence showing
that there was an intent not to protect the consumer, but rather to
exclude providers from providing appropriate products, it is unlikely that any violation would occur. Of course, that analysis
would require a full discussion of motive in a hearing on the merits.
Unfortunately, any discussion of the antitrust risks of PROs
serving the entire community may become largely academic in the
near future. Competition has clearly come to health care delivery
through the development of alternative health systems and managed health systems such as health maintenance organizations, preferred provider organizations, and other arrangements. All those
arrangements typically share the characteristics of limiting providers and developing monetary incentives to restrict cost increases.
The likelihood that all these organizations will select the same PRO
to perform review is extremely small. Indeed, part of the way in
which these entities compete with one another is to develop their
own utilization review. What the organizations typically share,
however, is the focus on cost rather than quality-at least for the
short run. Thus, it is likely that any peer-review arrangement established by the organization will focus exclusively on reduction of
costs, perhaps to the exclusion of quality. While that may be consistent with increased competition, it is not necessarily consistent
with the consumer welfare. Nevertheless, it appears to be what the
short-term future has in store for us. 9

18. It could be argued that such conduct is not anti-competitive because the consequences are merely to lower the price to the consumer. However, the antitrust laws are
concerned not merely with producing the lowest price, but producing an unfettered price. To
the extent that such restrictions limit choice it could be argued that they are anti-competitive.
19. One of the unexplored areas is the extent to which variations from the "community
standard" by such alternative arrangements will produce the potential for malpractice liability for the participating physicians as well as the organization itself.

